All Stories

  1. Human-Induced Pluripotent Stem Cell Technology: Toward the Future of Personalized Psychiatry
  2. The impact of visual dysfunctions in recent-onset psychosis and clinical high-risk state for psychosis
  3. First-onset major depression during the COVID-19 pandemic: A predictive machine learning model
  4. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders
  5. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD
  6. Predicting New-Onset Psychiatric Disorders Throughout the COVID-19 Pandemic: A Machine Learning Approach
  7. No Sex Differences in Self-Reported Childhood Maltreatment in Major Depressive and Bipolar Disorders: A Retrospective Study
  8. Can personalized medicine mitigate confirmation bias in mental health?
  9. Anxiety Disorders
  10. Prediction of illness remission in patients with Obsessive-Compulsive Disorder with supervised machine learning
  11. Efficacy of bio- and neurofeedback for depression: a meta-analysis
  12. Elevated C-reactive protein levels across diagnoses: The first comparison among inpatients with major depressive disorder, bipolar disorder, or obsessive–compulsive disorder
  13. Suicide and Genetic Biomarkers: Toward Personalized Tailored-treatment with Lithium and Clozapine
  14. Expert opinion in panic disorder: The impact of COVID-19-related fears, protective devices, and lockdown on panic and agoraphobia
  15. Special issue editorial: Personalized medicine in psychiatry in the COVID-19 era: Fighting the impact of the pandemic on mental health
  16. Oxidative Stress in the Early Stage of Psychosis
  17. 253 Better and faster automatic sleep staging with artificial intelligence
  18. Experimental Drugs for Panic Disorder: An Updated Systematic Review
  19. Are anxiety disorders associated with accelerated ageing and cognitive decline? A multicenter italian study in middle aged and older patients and controls
  20. C-reactive protein in a naturalistic sample of inpatients with major depressive disorder, bipolar disorder and obsessive-compulsive disorder
  21. Childhood maltreatment history for guiding personalized antidepressant choice in major depressive disorder: Preliminary results from a systematic review
  22. New onset of mental disorders, lifestyle changes, and quality of relationships during COVID-19 in italian population
  23. Cognitive subtypes in recent onset psychosis: distinct neurobiological fingerprints?
  24. Association between age of cannabis initiation and gray matter covariance networks in recent onset psychosis
  25. COVID-19 and panic disorder: clinical considerations for the most physical of mental disorders
  26. Psychopharmacological treatment in borderline personality disorder: A pilot observational study in a real-world setting
  27. Impact of respiratory protective devices on respiration: Implications for panic vulnerability during the COVID-19 pandemic.
  28. Traces of Trauma: A Multivariate Pattern Analysis of Childhood Trauma, Brain Structure, and Clinical Phenotypes
  29. Religious Coping, Hopelessness, and Suicide Ideation in Subjects with First-Episode Major Depression: An Exploratory Study in the Real World Clinical Practice
  30. The Co-Morbidity between Bipolar and Panic Disorder in Fibromyalgia Syndrome
  31. Validation of the Bullying Scale for Adults - Results of the PRONIA-study
  32. ‘Precision’ or ‘personalized’ psychiatry: different terms – same content?
  33. Relapse prevention in panic disorder with pharmacotherapy: where are we now?
  34. Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study
  35. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine
  36. Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables
  37. “The Italian Study on Recovery 2” Phase 1: Psychometric Properties of the Recovery Assessment Scale (RAS), Italian Validation of the Recovery Assessment Scale
  38. Heart rate variability: Can it serve as a marker of mental health resilience?
  39. Personalized Clinical Approaches to Anxiety Disorders
  40. Alexithymia, suicide ideation, affective temperaments and homocysteine levels in drug naïve patients with post-traumatic stress disorder: an exploratory study in the everyday ‘real world’ clinical practice
  41. Alexithymia, resilience, somatic sensations and their relationships with suicide ideation in drug naïve patients with first‐episode major depression: An exploratory study in the “real world” everyday clinical practice
  42. Common and different neural markers in major depression and anxiety disorders: A pilot structural magnetic resonance imaging study
  43. A Novel Ensemble-Based Machine Learning Algorithm to Predict the Conversion From Mild Cognitive Impairment to Alzheimer's Disease Using Socio-Demographic Characteristics, Clinical Information, and Neuropsychological Measures
  44. Toward a personalized therapy for panic disorder: preliminary considerations from a work in progress
  45. Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System
  46. The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?
  47. A Novel Ensemble-Based Machine Learning Algorithm To Predict The Conversion From Mild Cognitive Impairment To Alzheimer’s Disease Using Socio-demographic Characteristics, Clinical Information And Neuropsychological Measures
  48. Neuroprogression in anxiety disorders
  49. Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018
  50. Anxiety Disorders
  51. The role of spatial store and executive strategy in spatial working memory: a comparison between patients with obsessive–compulsive disorder and controls
  52. A clinically-translatable machine learning algorithm for the prediction of Alzheimer’s disease conversion: further evidence of its accuracy via a transfer learning approach
  53. Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors
  54. Controlled-release pregabalin in the treatment of fibromyalgia
  55. Are there advances in pharmacotherapy for panic disorder? A systematic review of the past five years
  56. Commentary: Cognitive Behavioral Therapy vs. Eye Movement Desensitization and Reprocessing for Treating Panic Disorder: A Randomized Controlled Trial
  57. Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review
  58. The key role of body and its control mechanisms in Panic Disorder
  59. A focus on the adverse effects of clozapine
  60. A Clinically-Translatable Machine Learning Algorithm for the Prediction of Alzheimer’s Disease Conversion in Individuals with Mild and Premild Cognitive Impairment
  61. Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician’s perspective
  62. Mental health professionals’ attitudes towards mental illness: professional and cultural factors in the INTER NOS study
  63. Personality biomarkers of pathological gambling: A machine learning study
  64. Features of mood associated with high body weight in females with fibromyalgia
  65. Reduced cortical thickness and increased gyrification in generalized anxiety disorder: a 3 T MRI study
  66. Does gender influence cognitive function in non-psychotic depression?
  67. Precision Psychiatry: Personalized Clinical Approach to Depression
  68. Management of Treatment-Resistant Panic Disorder
  69. Atypical Antipsychotics in Major Depressive Disorder
  70. The revolution of personalized psychiatry: will technology make it happen sooner?
  71. Alexithymia and Suicide Risk in Psychiatric Disorders: A Mini-Review
  72. The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions
  73. Cariprazine (RGH-188): a new pharmacological target option for the treatment of schizophrenia, bipolar disorders and depression?
  74. Personalized Medicine in Psychiatry: Back to the Future
  75. Personalized medicine in panic disorder: where are we now? A meta-regression analysis
  76. The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review
  77. Current and Future Perspectives on the Major Depressive Disorder: Focus on Vortioxetine
  78. Short-Term Psychiatric Rehabilitation in Major Depressive and Bipolar Disorders: Neuropsychological-Psychosocial Outcomes
  79. Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews
  80. Does the “” Lose its Shine Over the Time? Assessment of Loss of Lithium Response in a Preliminary Sample of Bipolar Disorder Outpatients
  81. Latent classes of emotional and behavioural problems in epidemiological and referred samples and their relations to DSM-IV diagnoses
  82. The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders
  83. Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice
  84. Does neuropsychological performance impact on real-life functional achievements in obsessive-compulsive disorder? A preliminary study
  85. Suicide during Perinatal Period: Epidemiology, Risk Factors, and Clinical Correlates
  86. Mediation effect of recent loss events on weight gain in obese people who experienced childhood parental death or separation
  87. Inflammatory markers and suicidal attempts in depressed patients: A review
  88. An update of safety of clinically used atypical antipsychotics
  89. Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials
  90. Role of worry in patients with chronic tinnitus and sensorineural hearing loss: a preliminary study
  91. Comments on “Heart rate and respiratory response to doxapram in patients with panic disorder”
  92. The prevalence and predictors of bipolar and borderline personality disorders comorbidity: Systematic review and meta-analysis
  93. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine
  94. Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines
  95. Is there cardiac risk in panic disorder? An updated systematic review
  96. Bipolar Polypharmacy
  97. Atypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placebo-Controlled Clinical Trials
  98. Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review
  99. A comprehensive review on the efficacy of S-Adenosyl-L-methionine in Major Depressive Disorder.
  100. Different Effects of Cigarette Smoking on Neuropsychological Performance in Psychiatric Disorders
  101. Are Anxiety Disorders Associated with Accelerated Aging? A Focus on Neuroprogression
  102. Effect of family structure and TPH2 G-703T on the stability of dysregulation profile throughout adolescence
  103. The HPA axis in bipolar disorder: Systematic review and meta-analysis
  104. Panic Disorder, Is It Really a Mental Disorder? From Body Functions to the Homeostatic Brain
  105. The role of melatonin in mood disorders
  106. Psychiatric Disorders and Childhood Parental Loss in Obesity: Relationship with the Mode of Weight Gain
  107. Is there a role for pharmacogenetics in the treatment of panic disorder?
  108. Effects of Public Awareness and Stigmatization on Accurate and Timely Diagnosis of Bipolar Disorder
  109. Factor structure and reliability of the Italian adaptation of the Hypomania Check List-32, second revision (HCL-32-R2)
  110. Laboratory, Clinical and Therapeutic Features of Respiratory Panic Disorder Subtype
  111. Alexithymia, Suicide Ideation, C-Reactive Protein, and Serum Lipid Levels Among Outpatients with Generalized Anxiety Disorder
  112. Alexithymia, responsibility attitudes and suicide ideation among outpatients with obsessive-compulsive disorder: An exploratory study
  113. Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression
  114. Prevalence and clinical features associated to bipolar disorder–migraine comorbidity: a systematic review
  115. Novel investigational therapeutics for panic disorder
  116. Melatonergic Antidepressant Agomelatine in Depressive and Anxiety Disorders
  117. Childhood Trauma, Temperament, and Character in Subjects With Major Depressive Disorder and Bipolar Disorder
  118. Panic and the Brainstem: Clues from Neuroimaging Studies
  119. Alexithymia, suicidal ideation, and serum lipid levels among drug-naïve outpatients with obsessive-compulsive disorder
  120. Self-reported quality of life and clinician-rated functioning in mood and anxiety disorders: Relationships and neuropsychological correlates
  121. Treatment of Antipsychotic-Induced Hyperprolactinemia: An Update on the Role of the Dopaminergic Receptors D2 Partial Agonist Aripiprazole
  122. Cotard’s Syndrome: Clinical Case Presentation and Literature Review
  123. Are Respiratory Abnormalities Specific for Panic Disorder? A Meta-Analysis
  124. Insomnia as a predictor of high-lethality suicide attempts
  125. Effect of the serotonin transporter gene and of environment on the continuity of anxiety and depression traits throughout adolescence
  126. Efficacy and Safety of Long Acting Injectable Atypical Antipsychotics: A Review
  127. The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice
  128. Baseline respiratory parameters in panic disorder: A meta-analysis
  129. Urinary incontinence and diarrhoea associated with the switch from oral to injectable risperidone
  130. Effects of Cigarette Smoking on Neuropsychological Performance in Mood Disorders
  131. S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study
  132. The somatic marker affecting decisional processes in obsessive-compulsive disorder
  133. Temperament, Character and Anxiety Sensitivity in Panic Disorder: A High-Risk Study
  134. The Relationships between Cholesterol and Suicide: An Update
  135. The “Emotional Side” of Subjective Tinnitus
  136. Cardiorespiratory response to physical exercise and psychological variables in panic disorder
  137. Emerging drugs for panic disorder
  138. Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition
  139. Is there a hypersensitive visual alarm system in panic disorder?
  140. Novel Antidepressants and Panic Disorder: Evidence beyond Current Guidelines
  141. Panic Disorder Respiratory Subtype: Psychopathology, Laboratory Challenge Tests, and Response to Treatment
  142. Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature
  143. Acoustic startle response in panic disorder
  144. Tradução e adaptação transcultural do Questionário de Atividade Física Habitual
  145. Carbon dioxide-induced panic attacks and quantitative electroencephalogram in panic disorder patients
  146. Dizziness, migrainous vertigo and psychiatric disorders
  147. Freezing reaction in panic disorder patients associated with anticipatory anxiety
  148. Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders
  149. S.23.03 CO2 models in anxiety disorders
  150. Clonazepam in the treatment of psychiatric disorders: an update
  151. Antipanic Efficacy of Paroxetine and Polymorphism within the Promoter of the Serotonin Transporter Gene
  152. Anxiety Sensitivity in Children of Panic Disorder Patients
  153. Smoking and respiratory irregularity in panic disorder
  154. Comparison of the Treatment with Paroxetine and Reboxetine in Panic Disorder: A Randomized, Single-Blind Study
  155. Modulation of Hyperreactivity to 35% CO2 After One Week of Treatment With Paroxetine and Reboxetine
  156. Panic disorder: from respiration to the homeostatic brain
  157. Comparison of 35% carbon dioxide reactivity between panic disorder and eating disorder
  158. Anxiety sensitivity and modulation of the serotonergic system in patients with PD
  159. Approximate Entropy of Respiratory Patterns in Panic Disorder
  160. Language of dyspnea in panic disorder
  161. Selective serotonin re-uptake inhibitors beyond psychiatry: Are they useful in the treatment of severe, chronic, obstructive pulmonary disease?
  162. Lack of relationship between CO2 reactivity and serotonin transporter gene regulatory region polymorphism in panic disorder
  163. Vulnerability to 35% CO2 of panic disorder patients with a history of respiratory disorders
  164. Pregnancy and Respiratory Nocturnal Panic Attacks
  165. Anxiety sensitivity and 35% CO2 reactivity in patients with panic disorder
  166. Neurosteroid secretion in panic disorder
  167. The Effect of One-Week Treatment with Venlafaxine on 35% CO2 Hyperreactivity in Patients with Panic Disorder: An Open Study
  168. Serotonergic modulation of the balance system in panic disorder: An open study
  169. Antipanic Drug Modulation Of 35% CO2 Hyperreactivity and Short-Term Treatment Outcome
  170. Respiratory irregularity in respiratory subtype panic
  171. Respiration in Children at Risk for Panic Disorder
  172. Panic disorder: the role of the balance system
  173. The 35% CO 2 Hyperreactivity and Clinical Symptomatology in Patients With Panic Disorder After 1 Week of Treatment With Citalopram: An Open Study
  174. A Comparison of Citalopram and Paroxetine in the Treatment of Panic Disorder: A Randomized, Single-Blind Study
  175. Dopamine function in obsessive compulsive disorder: cortisol response to acute apomorphine stimulation
  176. Plasma levels of tumor necrosis factor-alpha in patients with panic disorder: effect of alprazolam therapy
  177. A segregation study of panic disorder in families of panic patients responsive to the 35% CO2 challenge
  178. Neuroanatomy of the panic-respiration system
  179. Sensitivity to 35% Carbon Dioxide in Patients With Generalized Anxiety Disorder
  180. A long-term prospective evaluation of first-degree relatives of panic patients who underwent the 35% CO2 challenge
  181. Growth hormone response to growth hormone-releasing hormone stimulation in obsessive–compulsive disorder
  182. CO 2 -Induced Panic Attacks: A Twin Study
  183. PLASMA CONCENTRATIONS OF INTERLEUKIN-1β, INTERLEUKIN-6 AND TUMOR NECROSIS FACTOR-α IN ANOREXIA AND BULIMIA NERVOSA
  184. Plasma Interleukin-1β and Tumor Necrosis Factor Concentrations in Obsessive–Compulsive Disorders
  185. Dopamine function in obsessive—compulsive disorder: Growth hormone response to apomorphine stimulation
  186. Asthma and panic attacks
  187. Anxiety sensitivity and 35% CO2 reactivity in panic patients
  188. Modification of 35% Carbon Dioxide Hypersensitivity Across One Week of Treatment With Clomipramine and Fluvoxamine
  189. CO2 challenge in nonclinical subjects
  190. The 35% CO2 challenge test in patients with social phobia
  191. Pharmacologic Effect of Imipramine, Paroxetine, and Sertraline on 35% Carbon Dioxide Hypersensitivity in Panic Patients
  192. Noradrenergic receptor sensitivity in obsessive-compulsive disorders: I. growth hormone response to clonidine stimulation
  193. Noradrenergic receptor sensitivity in obsessive compulsive disorder: II. Cortisol response to acute clonidine administration
  194. Panic attacks: a twin study
  195. Family history of panic disorder and hypersensitivity to CO2 in patients with panic disorder
  196. Citalopram and panic disorder
  197. Citalopram and panic disorder
  198. T-lymphocyte cholecystokinin-8 and beta-endorphin concentrations in eating disorders: I. Anorexia nervosa
  199. T-lymphocyte concentrations of cholecystokinin-8 and beta-endorphin in eating disorders: II. Bulimia nervosa
  200. Hypersensitivity to inhalation of carbon dioxide and panic attacks
  201. Menstrual cycle-related sensitivity to 35% CO2 in panic patients
  202. Sensitivity to 35% CO2 in healthy first-degree relatives of patients with panic disorder
  203. The 35% CO2 challenge in panic disorder: Optimization by receiver operating characteristic (ROC) analysis
  204. 35% CO2 challenge in panic and mood disorders
  205. α2-Adrenergic receptor sensitivity in panic disorder: II
  206. α2-Adrenergic receptor sensitivity in panic disorder: I
  207. Pharmacologic Effect of Toloxatone on Reactivity to the 35% Carbon Dioxide Challenge
  208. Subclinical impairment of lung airways in patients with panic disorder
  209. Plasma interleukin-1 beta concentrations in panic disorder
  210. 35% CO2 model in panic disorder: a genetic perspective
  211. Carbon dioxide/oxygen challenge test in panic disorder
  212. Prevalence of respiratory diseases in patients with panic and obsessive compulsive disorders
  213. Alpha-2-Adrenoceptor Sensitivity in Heroin Addicts with and without Previous Attention Deficit Disorder/Hyperactivity and Conduct Disorder
  214. DSM-III-R personality disorders in panic disorder
  215. Psychoimmunoendocrine Aspects of Panic Disorder
  216. DSM-III-R personality disorders in panic and obsessive-compulsive disorder: A comparison study
  217. Anxiety, depression, and suicide: epidemiology, pathophysiology, and prevention
  218. Respiration and Anxiety